Goldman Sachs Group, Inc. (The) restated their neutral rating on shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in a research report report published on Friday, Marketbeat.com reports. The brokerage currently has a $17.00 target price on the biopharmaceutical company’s stock.
A number of other analysts have also issued reports on FOLD. Zacks Investment Research lowered shares of Amicus Therapeutics from a hold rating to a sell rating in a research note on Wednesday, July 12th. BidaskClub upgraded shares of Amicus Therapeutics from a buy rating to a strong-buy rating in a research note on Wednesday, July 19th. Robert W. Baird reiterated an outperform rating and set a $12.00 price objective on shares of Amicus Therapeutics in a research note on Friday, June 30th. Chardan Capital reiterated a buy rating and set a $16.50 price objective (down previously from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Finally, ValuEngine upgraded shares of Amicus Therapeutics from a sell rating to a hold rating in a research note on Friday, June 9th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $18.07.
Shares of Amicus Therapeutics (NASDAQ FOLD) opened at 14.48 on Friday. The stock’s market capitalization is $2.38 billion. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $16.60. The company’s 50-day moving average is $14.16 and its 200 day moving average is $10.69.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. The firm had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same period in the previous year, the company posted ($0.40) earnings per share. On average, equities analysts forecast that Amicus Therapeutics will post ($1.32) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Amicus Therapeutics’ (FOLD) “Neutral” Rating Reiterated at Goldman Sachs Group, Inc. (The)” was first published by BBNS and is owned by of BBNS. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/amicus-therapeutics-fold-neutral-rating-reiterated-at-goldman-sachs-group-inc-the/1703058.html.
In related news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was acquired at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.40% of the company’s stock.
Several large investors have recently modified their holdings of FOLD. Janus Henderson Group PLC bought a new stake in shares of Amicus Therapeutics in the second quarter worth $70,762,000. Wellington Management Group LLP increased its stake in shares of Amicus Therapeutics by 358.4% in the first quarter. Wellington Management Group LLP now owns 5,341,132 shares of the biopharmaceutical company’s stock worth $38,083,000 after buying an additional 4,175,995 shares during the last quarter. Morgan Stanley increased its stake in shares of Amicus Therapeutics by 99.4% in the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock worth $43,696,000 after buying an additional 3,055,039 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Amicus Therapeutics in the first quarter worth $21,394,000. Finally, Farallon Capital Management LLC bought a new stake in shares of Amicus Therapeutics in the second quarter worth $30,210,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with our FREE daily email newsletter.